targetted inhalation therapies arikace late-stage clinical trials ntm-lung-infections


Delivering novel,
targeted therapies
to improve the lives
of patients
suffering from serious
orphan lung diseases.


Learn More

Insmed and ARIKAYCE are trademarks in the United States and various other countries.

Chronic, debilitating
NTM lung infections
are on the rise, with
no approved treatments *




ARIKAYCE is in development for a
once-a-day treatment.

arikace nebulizer

* "Khan_2007" Khan et al, 2007; "Marras_2007" Marras et al, 2007


Investor Presentation

View the latest Insmed Investor Presentation here.

Learn More

Our Team

Insmed's mission is to improve the lives of patients battling serious orphan lung diseases through novel, targeted inhalation therapies in patient populations with critical unmet needs.

Learn More